SLC5A2 and diabetic ketoacidosis: The risk of diabetic ketoacidosis was previously highlighted by clinical trials [8,9,10,11] and then by the Pharmacovigilance Risk Assessment Committee of EMA for the entire drug class of SGLT-2 inhibitors [12].